- Home
- AVTX vs MITT Comparison
AVTX vs MITT Comparison
Compare AVTX & MITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | MITT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 258.7M |
| IPO Year | 2015 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AVTX | MITT |
|---|---|---|
| Price | $19.09 | $8.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $32.29 | $8.60 |
| AVG Volume (30 Days) | ★ 298.2K | 186.0K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 10.59% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.94 |
| Revenue | $192,000.00 | ★ $87,678,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.68 |
| P/E Ratio | ★ N/A | $9.26 |
| Revenue Growth | N/A | ★ 8.59 |
| 52 Week Low | $3.39 | $5.63 |
| 52 Week High | $20.72 | $8.81 |
Technical Indicators
Market Signals| Indicator | AVTX | MITT |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 79.18 |
| Support Level | $17.18 | $8.32 |
| Resistance Level | $20.20 | $8.22 |
| Average True Range (ATR) | 1.72 | 0.16 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 69.94 | 96.75 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.